402 related articles for article (PubMed ID: 26314963)
1. Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene.
Wang L; Cai W; Zhang W; Chen X; Dong W; Tang D; Zhang Y; Ji C; Zhang M
Oncotarget; 2015 Sep; 6(29):27490-504. PubMed ID: 26314963
[TBL] [Abstract][Full Text] [Related]
2. Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling.
Pulikkan JA; Madera D; Xue L; Bradley P; Landrette SF; Kuo YH; Abbas S; Zhu LJ; Valk P; Castilla LH
Blood; 2012 Jul; 120(4):868-79. PubMed ID: 22613795
[TBL] [Abstract][Full Text] [Related]
3. High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects.
Li X; Li C; Jin J; Wang J; Huang J; Ma Z; Huang X; He X; Zhou Y; Xu Y; Yu M; Huang S; Yan X; Li F; Pan J; Wang Y; Yu Y; Jin J
EBioMedicine; 2018 Dec; 38():47-56. PubMed ID: 30472087
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells.
Okuda A; Kurokawa S; Takehashi M; Maeda A; Fukuda K; Kubo Y; Nogusa H; Takatani-Nakase T; Okuda S; Ueda K; Tanaka S
BMC Neurosci; 2017 Jan; 18(1):14. PubMed ID: 28095779
[TBL] [Abstract][Full Text] [Related]
5. BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib.
Faraoni I; Compagnone M; Lavorgna S; Angelini DF; Cencioni MT; Piras E; Panetta P; Ottone T; Dolci S; Venditti A; Graziani G; Lo-Coco F
Biochim Biophys Acta; 2015 Mar; 1852(3):462-72. PubMed ID: 25483710
[TBL] [Abstract][Full Text] [Related]
6. T315 Decreases Acute Myeloid Leukemia Cell Viability through a Combination of Apoptosis Induction and Autophagic Cell Death.
Chiu CF; Weng JR; Jadhav A; Wu CY; Sargeant AM; Bai LY
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27537872
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis.
Martin-Oliva D; Aguilar-Quesada R; O'valle F; Muñoz-Gámez JA; Martínez-Romero R; García Del Moral R; Ruiz de Almodóvar JM; Villuendas R; Piris MA; Oliver FJ
Cancer Res; 2006 Jun; 66(11):5744-56. PubMed ID: 16740713
[TBL] [Abstract][Full Text] [Related]
8. PARP-1 Overexpression as an Independent Prognostic Factor in Adult Non-M3 Acute Myeloid Leukemia.
Pashaiefar H; Yaghmaie M; Tavakkoly-Bazzaz J; Ghaffari SH; Alimoghaddam K; Momeny M; Izadi P; Izadifard M; Kasaeian A; Ghavamzadeh A
Genet Test Mol Biomarkers; 2018 Jun; 22(6):343-349. PubMed ID: 29812960
[TBL] [Abstract][Full Text] [Related]
9. Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors.
Esposito MT; Zhao L; Fung TK; Rane JK; Wilson A; Martin N; Gil J; Leung AY; Ashworth A; So CW
Nat Med; 2015 Dec; 21(12):1481-90. PubMed ID: 26594843
[TBL] [Abstract][Full Text] [Related]
10. TWIST-1 promotes cell growth, drug resistance and progenitor clonogenic capacities in myeloid leukemia and is a novel poor prognostic factor in acute myeloid leukemia.
Wang N; Guo D; Zhao YY; Dong CY; Liu XY; Yang BX; Wang SW; Wang L; Liu QG; Ren Q; Lin YM; Ma XT
Oncotarget; 2015 Aug; 6(25):20977-92. PubMed ID: 26023795
[TBL] [Abstract][Full Text] [Related]
11. High expression of BCAT1 sensitizes AML cells to PARP inhibitor by suppressing DNA damage response.
Pan J; Wang Y; Huang S; Mao S; Ling Q; Li C; Li F; Yu M; Huang X; Huang J; Lv Y; Li X; Ye W; Wang H; Wang J; Jin J
J Mol Med (Berl); 2024 Mar; 102(3):415-433. PubMed ID: 38340163
[TBL] [Abstract][Full Text] [Related]
12. The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-κB activation.
Faraoni I; Aloisio F; De Gabrieli A; Consalvo MI; Lavorgna S; Voso MT; Lo-Coco F; Graziani G
Cancer Lett; 2018 Jun; 423():127-138. PubMed ID: 29526802
[TBL] [Abstract][Full Text] [Related]
13. Neuropilin-1 modulates vascular endothelial growth factor-induced poly(ADP-ribose)-polymerase leading to reduced cerebrovascular apoptosis.
Mey L; Hörmann M; Schleicher N; Reuter P; Dönges S; Kinscherf R; Gassmann M; Gerriets T; Al-Fakhri N
Neurobiol Dis; 2013 Nov; 59():111-25. PubMed ID: 23816753
[TBL] [Abstract][Full Text] [Related]
14. Emodin enhances ATRA-induced differentiation and induces apoptosis in acute myeloid leukemia cells.
Chen Y; Li J; Hu J; Zheng J; Zheng Z; Liu T; Lin Z; Lin M
Int J Oncol; 2014 Nov; 45(5):2076-84. PubMed ID: 25174432
[TBL] [Abstract][Full Text] [Related]
15. PARP inhibition restores erectile function by suppressing corporal smooth muscle apoptosis in diabetic rats.
Li WJ; Zhou J; Li B; Wang H; Peng YB; Wang Z
J Sex Med; 2011 Apr; 8(4):1072-82. PubMed ID: 21235725
[TBL] [Abstract][Full Text] [Related]
16. Different regulation of PARP1, PARP2, PARP3 and TRPM2 genes expression in acute myeloid leukemia cells.
Gil-Kulik P; Dudzińska E; Radzikowska-Büchner E; Wawer J; Jojczuk M; Nogalski A; Wawer GA; Feldo M; Kocki W; Cioch M; Bogucka-Kocka A; Rahnama M; Kocki J
BMC Cancer; 2020 May; 20(1):435. PubMed ID: 32423430
[TBL] [Abstract][Full Text] [Related]
17. [Study of thrombopoietin and its receptor C-mpl in acute leukemia].
Guo Y; Bian S; Luo M
Zhonghua Xue Ye Xue Za Zhi; 1999 Mar; 20(3):120-3. PubMed ID: 11601235
[TBL] [Abstract][Full Text] [Related]
18. Expression of the receptor MPL and proliferative effects of its ligand thrombopoietin on human leukemia cells.
Quentmeier H; Zaborski M; Graf G; Ludwig WD; Drexler HG
Leukemia; 1996 Feb; 10(2):297-310. PubMed ID: 8637239
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
20.
Molenaar RJ; Radivoyevitch T; Nagata Y; Khurshed M; Przychodzen B; Makishima H; Xu M; Bleeker FE; Wilmink JW; Carraway HE; Mukherjee S; Sekeres MA; van Noorden CJF; Maciejewski JP
Clin Cancer Res; 2018 Apr; 24(7):1705-1715. PubMed ID: 29339439
[No Abstract] [Full Text] [Related]
[Next] [New Search]
